Fp. O'Malley et al., Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry, AM J CLIN P, 115(4), 2001, pp. 504-511
Citations number
45
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
We prospectively evaluated a series of 254 breast cancers by quantitative p
olymerase chain reaction (PCR) and immunohistochemistry using 3 antibodies:
HercepTest, CB11, and TAB250. DNA was extracted from a 10-mum tumor sectio
n for PCR, and 4-mum serial sections were taken from the same block for imm
unohistochemistry. The immunohistochemical results were scored using a semi
quantitative immunohistochemical system. A positive tumor by immunohistoche
mistry had a score of 5 or more. The manufacturer's recommended scoring sys
tem was used for the HercepTest. Tumors were positive for gene amplificatio
n if the ratio of the HER2/neu gene to control gene after normalization was
2 or more. Of 254 cases, 61 showed gene amplification. For immunohistochem
istry, 23% of tumors were positive with CB11, 27% with TAB250, and 37% with
the HercepTest. Results for each antibody were compared with PCR results.
The overall concordance for the HercepTest was 82%, which was significantly
lower than that for CB11 (88%) or TAB250 (87%). The specificity for the He
rcepTest was 80% compared with 90% for TAB250 and 93% for CB11, while the p
ositive predictive value for the HercepTest was 57% compared with 71% and 7
6% for TAB250 and CB11, respectively.